Detalhe da pesquisa
1.
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.
Gynecol Oncol
; 163(2): 274-280, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34452745
2.
RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer.
Future Oncol
; 17(26): 3433-3443, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34409858